MedPath

Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients

Phase 4
Completed
Conditions
Human Immunodeficiency Virus
Interventions
Registration Number
NCT00648999
Lead Sponsor
AbbVie (prior sponsor, Abbott)
Brief Summary

To demonstrate that patients treated with Kaletra have an improvement in their quality of life compared to the quality of life they had with their previous NRTI therapy.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
207
Inclusion Criteria
  • HIV Infected subjects
  • Subjects failing in current HIV treatment, or
  • Subjects with a viral load < 400 copies/mL and not tolerating their current HIV treatment.
Exclusion Criteria
  • Subject is currently participating in another clinical study or has participated in another clinical study within 30 days prior to screening visit
  • Subject is pregnant

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
2lopinavir/ritonavir-
1lopinavir/ritonavir-
Primary Outcome Measures
NameTimeMethod
Quality of LifeBaseline, Week 4, Week 24 and Week 48
CD4Baseline, Week 24 and Week 48
Secondary Outcome Measures
NameTimeMethod
Adverse Event MonitoringBaseline, Week 4, Week 24 and Week 48

Trial Locations

Locations (13)

Site Ref # / Investigator 4049

๐Ÿ‡ฒ๐Ÿ‡ฝ

Mexico City, Distrito Federal, Mexico

Site Ref # / Investigator 4052

๐Ÿ‡ฒ๐Ÿ‡ฝ

Oaxaca, Mexico

Site Ref # / Investigator 4055

๐Ÿ‡ฒ๐Ÿ‡ฝ

Culiacan, Sinaloa, Mexico

Site Ref # / Investigator 4051

๐Ÿ‡ฒ๐Ÿ‡ฝ

Mexico City, Distrito Federal, Mexico

Site Ref # / Investigator 4077

๐Ÿ‡ฒ๐Ÿ‡ฝ

Mexico City, Distrito Federal, Mexico

Site Ref # / Investigator 4074

๐Ÿ‡ฒ๐Ÿ‡ฝ

Leon, Guanajauto, Mexico

Site Ref # / Investigator 4072

๐Ÿ‡ฒ๐Ÿ‡ฝ

Tepic, Nayarit, Mexico

Site Ref # / Investigator 4054

๐Ÿ‡ฒ๐Ÿ‡ฝ

Morelia, Michoacan, Mexico

Site Ref # / Investigator 4053

๐Ÿ‡ฒ๐Ÿ‡ฝ

Puebla, Mexico

Site Ref # / Investigator 4073

๐Ÿ‡ฒ๐Ÿ‡ฝ

Chihuahua, Mexico

Site Ref # / Investigator 4050

๐Ÿ‡ฒ๐Ÿ‡ฝ

Mexico City, Distrito Federal, Mexico

Site Ref # / Investigator 4056

๐Ÿ‡ฒ๐Ÿ‡ฝ

Mexico City, Distrito Federal, Mexico

Site Ref # / Investigator 4075

๐Ÿ‡ฒ๐Ÿ‡ฝ

Merida, Yucatan, Mexico

ยฉ Copyright 2025. All Rights Reserved by MedPath